Predicting future cognitive impairment in preclinical Alzheimer’s disease using amyloid PET and MRI: a multisite machine learning study

Braden Yang, Tom Earnest, Murat Bilgel, Marilyn Albert, Sterling C. Johnson, Christos Davatzikos, Güray Erus, Colin L. Masters, Susan M. Resnick, Michael I. Miller, Arnold Bakker, John C. Morris, Tammie L.s. Benzinger, Brian A. Gordon, Aristeidis Sotiras, the Alzheimer’s Disease Neuroimaging InitiativemedRxiv 2025 · DOI

Abstract

Predicting the likelihood of developing Alzheimer's disease (AD) dementia in at-risk individuals is critical for the design and recruitment of clinical trials for disease-modifying therapies. While machine learning (ML) has shown promise in this area, there is a lack of models specifically for the preclinical AD population—individuals who show early signs of abnormal brain amyloidosis but remain cognitively unimpaired. In this study, we trained and evaluated ML classifiers to predict whether individuals with preclinical AD would progress to mild cognitive impairment (MCI) or dementia within fixed time windows ranging from one to five years. Using regional imaging features from amyloid PET and MRI pooled across seven independent sites and two radiotracers, our models achieved out-of-sample receiver operating characteristic area-under-the-curve (ROC-AUC) values of 0.66 or greater. Furthermore, retroactive cohort enrichment analysis on A4 clinical trial data demonstrated increased statistical power to detect treatment effects. These findings underscore the potential of ML-based patient stratification to improve the efficiency of future clinical trials.

Introduction

Alzheimer’s Disease (AD) clinical trials face a notoriously high failure rate, often because interventions occur too late in the disease progression. Consequently, research has shifted toward the preclinical stage—identifying individuals who are "amyloid-positive" (possessing protein plaques) but still cognitively normal.

However, preclinical AD is highly heterogeneous; while some individuals remain stable for years, others decline rapidly. This variance poses a significant challenge for clinical trials: if a cohort includes too many "stable" individuals, the efficacy of a drug may be masked by a lack of measurable decline in the group. This study addresses this challenge by developing a generalizable machine learning framework to predict progression from preclinical AD to symptomatic stages within one to five years.

Methodology

Machine Learning Framework

The researchers employed Support Vector Machines (SVM) with linear kernels to perform binary classification (Stable vs. Progressor). To capture the nuances of disease progression, they trained five separate models corresponding to different "time-to-progression" windows (1, 2, 3, 4, and 5 years).

Multimodal Feature Integration

The models integrated several data types to maximize predictive accuracy:

  • Amyloid PET (SUVR): Regional amyloid signals, rather than just global averages.
  • Structural MRI: Regional brain volumes to detect early atrophy.
  • Non-Imaging Factors: Age, sex, and the presence of the APOE4 genotype.

Validation and Generalizability

To ensure the models were not overfitted to specific hospital data, the team utilized leave-one-site-out and leave-one-tracer-out cross-validation. This tested the models' ability to generalize across different PET scanners and chemical tracers ([18F]-florbetapir and [11C]-PiB) without specific site-based tuning.

Data Sources

The study pooled data from seven independent sites, creating a robust dataset of 343 stable individuals and 247 progressors. Data sources included:

  • A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s)
  • ADNI (Alzheimer’s Disease Neuroimaging Initiative)
  • HABS (Harvard Aging Brain Study)
  • MCSA (Mayo Clinic Study of Aging)
  • OASIS (Open Access Series of Imaging Studies)
  • PAC (Preclinical AD Consortium)

Key Insights

The Value of Regional Patterns

While clinical eligibility often relies on a single "global" amyloid score, this study found that regional patterns—specifically within the temporal and frontal cortices—are significantly more sensitive markers for imminent cognitive decline.

The "Amyloid Lead" Effect

Analysis of feature importance revealed that amyloid PET features became increasingly dominant as the prediction window lengthened (e.g., 5-year vs. 1-year predictions). This suggests that specific amyloid deposition patterns act as an early-warning system that precedes measurable structural brain atrophy captured by MRI.

Clinical Trial Enrichment

A retroactive analysis of the A4 trial provided a proof-of-concept for "cohort enrichment." By using the ML model to filter participants to only those predicted to decline, the researchers demonstrated that treatment effects could be detected with significantly smaller sample sizes. For a sample size of 40 per group, the statistical power to detect differences in amyloid accumulation jumped from ~40% (unenriched) to ~65% (ML-enriched).

Results and Generalizability

The classifiers demonstrated strong performance across diverse datasets:

  • Site Generalizability: Out-of-sample ROC-AUC scores ranged from 0.66 to 0.96 for most sites.
  • Tracer Agnosticism: When tested on entirely unseen radiotracers, the models maintained an AUC of 0.72 or higher, proving they can function across different clinical environments.

Limitations and Future Directions

Despite the success of the SVM models, the study noted that the preclinical population remains difficult to recruit, leading to smaller sample sizes than those typically used in deep learning. This necessitated the use of traditional ML over complex architectures like Transformers.

Additionally, because each time-window model was trained independently, there is a risk of temporal inconsistency (e.g., predicting stability at 5 years but decline at 2 years). Future research will explore survival SVMs or time-to-event models to ensure longitudinal consistency. Finally, the poor performance at one specific site (HABS) highlighted that extreme class imbalance and small local samples remain a challenge for universal ML application.

Conclusion

As the search for disease-modifying therapies for Alzheimer’s moves toward asymptomatic populations, ML-based stratification offers a path toward more efficient clinical trials. By identifying the individuals most likely to decline, researchers can build more homogeneous cohorts, increasing the statistical power to identify life-changing treatments.

Summary updated

Abstract

Predicting the likelihood of developing Alzheimer's disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitment for clinical trials of disease-modifying therapies. Machine learning (ML) has been shown to excel in this task; however, there remains a lack of models developed specifically for the preclinical AD population, who display early signs of abnormal brain amyloidosis but remain cognitively unimpaired. Here, we trained and evaluated ML classifiers to predict whether individuals with preclinical AD will progress to mild cognitive impairment or dementia within multiple fixed time windows, ranging from one to five years. Models were trained on regional imaging features extracted from amyloid positron emission tomography and magnetic resonance imaging pooled across seven independent sites and from two amyloid radiotracers ([<sup>18</sup>F]-florbetapir and [<sup>11</sup>C]-Pittsburgh-compound-B). Out-of-sample generalizability was evaluated via a leave-one-site-out and leave-one-tracer-out cross-validation. Classifiers achieved an out-of-sample receiver operating characteristic area-under-the-curve of 0.66 or greater when applied to all except one hold-out sites and 0.72 or greater when applied to each hold-out radiotracer. Additionally, when applying our models in a retroactive cohort enrichment analysis on A4 clinical trial data, we observed increased statistical power of detecting differences in amyloid accumulation between placebo and treatment arms after enrichment by ML stratifications. As emerging investigations of new disease-modifying therapies for AD increasingly focus on asymptomatic, preclinical populations, our findings underscore the potential applicability of ML-based patient stratification for recruiting more homogeneous cohorts and improving statistical power for detecting treatment effects for future clinical trials.
BibTeX
@misc{yang2025predicting,
  author = {Braden Yang and Tom Earnest and Murat Bilgel and Marilyn Albert and Sterling C. Johnson and Christos Davatzikos and Güray Erus and Colin L. Masters and Susan M. Resnick and Michael I. Miller and Arnold Bakker and John C. Morris and Tammie L.S. Benzinger and Brian A. Gordon and Aristeidis Sotiras and the Alzheimer’s Disease Neuroimaging Initiative},
  title = {{Predicting future cognitive impairment in preclinical Alzheimer’s disease using amyloid PET and MRI: a multisite machine learning study}},
  year = {2025},
  doi = {10.1101/2025.10.15.25337507},
  howpublished = {medRxiv},
}
Figure